Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
about
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
description
2019 nî lūn-bûn
@nan
2019年の論文
@ja
2019年学术文章
@wuu
2019年学术文章
@zh
2019年学术文章
@zh-cn
2019年学术文章
@zh-hans
2019年学术文章
@zh-my
2019年学术文章
@zh-sg
2019年學術文章
@yue
2019年學術文章
@zh-hant
name
Health-related quality of life ...... tre, open-label, phase 3 trial
@en
type
label
Health-related quality of life ...... tre, open-label, phase 3 trial
@en
prefLabel
Health-related quality of life ...... tre, open-label, phase 3 trial
@en
P2093
P1433
P1476
Health-related quality of life ...... tre, open-label, phase 3 trial
@en
P2093
Christina Schaub
Christoph Coch
Clemens Seidel
Dietmar Krex
Frederic Mack
Joachim Peter Steinbach
Johannes Weller
Lars Bullinger
Martin Glas
Martin Uhl
P304
P356
10.1016/S1470-2045(19)30502-9
P577
2019-09-02T00:00:00Z